Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026

뉴스 본문을 불러오고 있어요.

Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026 | 웨이프 WAPE

Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026

기사 요약

관련 종목

댓글 —